Beta alethine

Drug Profile

Beta alethine

Alternative Names: Alethine beta; Beta LT; Betathine

Latest Information Update: 16 May 2007

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator University of New Mexico
  • Developer LifeTime Pharmaceuticals
  • Class Small molecules
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Multiple myeloma

Highest Development Phases

  • Discontinued Lymphoma; Macroglobulinaemia; Multiple myeloma; Non-Hodgkin's lymphoma

Most Recent Events

  • 30 Apr 2002 LifeTime Pharmaceuticals has acquired all the intellectual property covering beta alethine from Dovetail
  • 30 Nov 2001 Phase-I/II in early multiple myeloma and MGUS in USA (unknown route)
  • 31 Aug 2000 Phase-I/II clinical trials for Lymphoma in USA (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top